TriangleCyclosporine (NCT03128034)
Cyclosporine trial for Acute Lymphoblastic Leukemia (NCT03128034). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
For high-risk acute leukemia, a donor transplant can cure, but only if conditioning clears enough disease, and stronger conditioning damages the whole body.
The idea: deliver radiation by antibody, straight to blood cells, using a particle that travels only a few cell widths.
At Fred Hutch in Seattle, an antibody against CD45, a marker on nearly all blood and leukemia cells, is labeled with astatine-211. Astatine emits alpha particles: heavy, intensely damaging, spent within a few cells' distance. Given a week before transplant, it targets the marrow and leukemia while sparing tissue beyond. Then fludarabine, low-dose total-body irradiation, and the donor's cells follow.
A dose-finding study in adults. Brenda Sandmaier leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.